The 2018 ESMO Clinical Practice Guidelines for diagnosis, treatment and follow‐up of HCC recommend that ramucirumab can be considered as second‐line treatment after sorafenib of patients with baseline AFP ≥400 ng/mL, well‐preserved liver function and ECOG Performance Status 0 or 1.12 Here, AFP is linked to hepatocellular carcinoma.